What Did the New Study Find?
A recent observational study published in The Lancet Regional Health Europe examined the health records of over 80,000 people with type 2 diabetes in Italy. It found that patients who stopped taking GLP-1 medications had approximately double the risk
of experiencing a major cardiovascular event—such as a non-fatal heart attack or stroke—or death from any cause, compared to those who continued the treatment. Specifically, researchers noted that for every 100 people who stopped treatment, about four had a major adverse event per year, compared to about two per 100 people who stayed on the medication. The study observed that a majority of patients, around 60%, discontinued their therapy after about one year. This has raised significant questions about the long-term management of chronic conditions with these drugs.
Why 'No Direct Causation' Is the Key Takeaway
The most crucial point from the researchers is that this study does not prove that stopping the drug causes heart attacks or strokes. Because it was an observational study, it can only show a correlation, or a link, between two things—in this case, discontinuing the medication and experiencing a negative health outcome. It cannot establish a cause-and-effect relationship. The researchers themselves caution that discontinuing the medication might simply be a 'marker of higher underlying risk'. This distinction is vital because it prevents jumping to the conclusion that stopping the drug is inherently dangerous in itself.
What Else Could Explain the Increased Risk?
There are several other possible explanations, known as confounding factors, for the findings. The study did not analyze why people stopped taking the medication. Patients may have stopped because they were already in poorer health, or because of an illness that independently increased their cardiovascular risk. Other common reasons for discontinuation include significant side effects like gastrointestinal issues, high costs, or loss of insurance coverage. In these scenarios, the adverse health outcome might be linked to the underlying reason for stopping, not the act of stopping itself. For example, if a patient stops because of a new, unrelated illness, that illness could be the true cause of a subsequent heart attack.
The Protective Benefits Simply Fade
Another way to interpret the findings is not that stopping the drug causes harm, but that it simply ends the protection the drug provides. GLP-1s are known to have cardiovascular benefits beyond blood sugar control and weight loss. When the medication is withdrawn, those protective effects are lost. The body's blood sugar, blood pressure, and weight often return to their pre-medication levels, which in turn brings back the original, higher risk of cardiovascular problems. One cardiologist described the findings as 'reproving' that these medications protect the heart, so when you remove that protection, the baseline risk returns. Essentially, the benefits are drug-dependent and fade upon cessation.
What Does This Mean for Patients?
The primary takeaway for patients is that GLP-1s are designed as long-term treatments for chronic conditions like type 2 diabetes and obesity. The findings underscore the importance of continuous use to maintain the health benefits. Discontinuing the medication should be a deliberate decision made in close consultation with a doctor. If side effects or costs are a concern, it is crucial to discuss alternative treatments rather than simply stopping. For those who have reached their weight loss goals, a maintenance plan is necessary, as stopping the drug without a strategy often leads to weight regain and the reversal of metabolic improvements. This study doesn't suggest the drugs are unsafe; rather, it highlights that their benefits are tied to their continued use.
















